Reflections on the IJHPR’s article collection on dementia

Jill Harrison1*, Vincent Mor1,2, Susan Mitchell3,4 and Ellen P. McCarthy3,4

Abstract
Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) constitute a worldwide public health crisis. In light of the AD/ADRD epidemic now existing within the global COVID-19 pandemic, the need for global action to improve dementia care is greater than ever. The article collection “Dementia- an Interdisciplinary Approach,” in the Israeli Journal of Health Policy and Research (IJHPR) highlights the need for interprofessional approaches to improving outcomes for people living with dementia and their care partners, as well as the complexities of conducting dementia care research.

Keywords: Dementia care, Alzheimer’s disease, Pragmatic clinical trials, Non-pharmacological interventions

Dementia- a global epidemic
Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) are a group of irreversible and progressive brain disorders that manifest across a continuum of cognitive decline, including difficulty in eating, speaking, problem-solving, making decisions, and memory loss that interfere with a person’s daily activities [1, 2]. Current estimates indicate that 50 million people worldwide live with AD/ADRD [3]. The World Health Organization estimates that the number will triple to more than 150 million people affected globally by 2050 [4]. The global prevalence of dementia varies due to a variety of factors and can be difficult to estimate in some regions [5]. Worldwide, AD/ADRD leaves relatively few populations untouched. It is estimated that someone in the world develops dementia every 3 s [6]. As a disease that exists across a variety of diverse cultures in the world, there is a global population health imperative to develop culturally specific and congruent approaches to provide dementia care.

Global action to improve dementia care
The article collection “Dementia- an Interdisciplinary Approach,” in the Israeli Journal of Health Policy and Research (IJHPR) [7] highlights the need for multidimensional, interprofessional, and internationally collaborative approaches to improve dementia care. The illuminating seven-article series highlights important issues in dementia care including the use of home hospice in cases of advanced dementia [8], ethical, regulatory and legal challenges to conducting clinical research in dementia [9, 10], and the ways in which depictions of dementia in contemporary movies influences the social valuation of the disease [11]. Taken together, these articles emphasize the need for national and global action to improve dementia care.

What is the NIA IMPACT Collaboratory?
The National Institute on Aging (NIA) IMbedded Pragmatic Alzheimer’s Disease (AD) and AD-Related Dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory is part of a national response intended to transform the delivery of dementia care in health care systems in the United States [3]. The IMPACT Collaboratory has created a nationwide infrastructure funded through a cooperative agreement from the National

* Correspondence: jill_s_harrison@brown.edu
1Department of Health Services, Policy, and Practice, School of Public Health, Brown University, Box G-S121 (6), Providence, RI 02912, USA
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Institute on Aging in order to promote the conduct of embedded Pragmatic Clinical Trials (ePCTs) that evaluate non-pharmacological approaches to care for people living with dementia (PLWD) and their care partners within healthcare systems. This is being accomplished by a coordinated effort of multidisciplinary experts from across the U.S., organized into 10 Working Cores Groups and Teams whose expert members partner with health care system leaders and key stakeholders to develop and disseminate best practice research methods, build investigator capacity through training and knowledge generation, catalyze collaboration among stakeholders, and ensure that dementia research includes culturally-tailored interventions for people from diverse and under-represented backgrounds.

As part of the Collaboratory’s mission to support the design and conduct of ePCTs, a national pilot study award program was established to fund approximately 40 studies over a five-year period with the aim of accelerating tests of nonpharmacologic interventions embedded in everyday clinical practice to improve dementia care [12]. Unlike traditional clinical trials that test interventions under highly controlled conditions, pilot ePCTs test whether dementia care interventions work when they are embedded into everyday healthcare settings under real-world conditions [13]. Pilot ePCTs have tremendous potential to close the science-to-service gap, as described by Golander in the description of mini-research projects as a mechanism to improve the quality of dementia care [14] and by Sternberg and colleagues in their pilot study of home hospice for severe dementia [8].

ePCTs are designed to inform clinical and policy-level decisions about dementia care that works in the real-world. Co-authors Bentur & Sternberg [15] explore several ways in which ePCTs bridge research and practice in their discussion of top-down and bottom-up approaches to optimize the relevancy of trials to stakeholders’ everyday lives. The convergence of policy/regulatory/researcher-initiated research (referred to as top-down approaches), with interventions initiated by clinical and lived experience and knowledge of being immersed in daily dementia care (referred to as bottom-up approaches) is the dynamic needed not only to improve the person-centeredness of dementia research [16], but also its uptake, adoption, and implementation by the intended end-users [17].

An epidemic within a pandemic
The IJHPR article collection on dementia was curated prior to the insidious global spread of the novel Coronavirus. Since early 2020, the global dementia epidemic now exists within the COVID-19 pandemic. AD/ADRD and COVID-19 are both international public-health crises that disproportionately impact older adults and, for both, there are no known effective medical treatments. Non-drug interventions, such as masks, social distancing, and hand hygiene are being deployed world-wide in the fight against COVID-19. Some of these critical infection control practices have unintended consequences for dementia care. For example, people living with dementia may be confused at the sight of care partners in masks and may refuse or be unable to wear one themselves. Social distancing and quarantine orders to prevent virus spread compound social isolation of people living with dementia, a factor that is associated with incidence and severity of AD/ADRD [18].

We are learning more about the experiences of PLWD in long-term care facilities during COVID-19, in which many residents have been restricted from seeing family and friends. However, we know very little about the experiences of PLWD living alone in the context of COVID and about the pandemic’s impact on caregivers living in the community. These include the impact on PLWD in alternative care arrangements, such as the shared housing arrangements in Germany, described by Gräske, Schmidt, and Wolf-Ostermann in their article in the IJHPR collection [19]. The caregiver burden for Alzheimer’s, in Israel and other nations, was already extremely high before the pandemic [15]. The financial burdens and stress for caregivers, often referred to as “second patients,” are likely to compound as a result of a variety of COVID-related factors such as social isolation, economic hardship associated with changes to employment, limited access to supportive services and the intersection of multiple caregiving roles as a result of school closures. More research is needed to build knowledge about living with dementia and caregiving in the context of COVID, including its impact on health equity [20] and how societies can build their capacity to anticipate and address disparities.

Conclusion
The issues addressed in the IJHPR article collection have never been more salient and will undoubtedly continue to have international resonance as the world looks to respond to the unmet needs of people living with dementia and care partners. The application of the issues raised in the article collection to other settings and other cultures will be a critical agenda for research and practice for years to come. In light of the AD/ADRD epidemic now existing within a global pandemic, the need for global action to improve dementia care has never been greater. The current intersection of these health crises is a much-needed wake-up call as we prepare for the certainty of an uncertain future. Will we be better prepared the next time?

Abbreviations
PLWD: Person living with dementia; ePCT: Embedded pragmatic clinical trial
Authors’ contributions
All authors contributed to the writing of this commentary. All authors read and approved the final manuscript.

Funding
This work was supported by the National Institute of Aging (NIA) of the National Institutes of Health (NIH) under Award Number U54AG063546, which funds NIA Imbedded Pragmatic Alzheimer’s Disease and AD-Related Dementias Clinical Trials Collaboratory (NIA IMPACT Collaboratory). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Availability of data and materials
N/A.

Ethics approval and consent to participate
N/A.

Consent for publication
N/A.

Competing interests
The authors declare they have no competing interests.

Author details
1. Department of Health Services, Policy, and Practice, School of Public Health, Brown University, Box G-S121 (6), Providence, RI 02912, USA.
2. Providence Veterans Administration Medical Center, Center of Innovation in Health Services Research and Development Service, Providence, RI, USA.
3. Hebrew SeniorLife Hinda and Arthur Marcus Institute for Aging Research, Boston, MA, USA.
4. Beth Israel Deaconess Medical Center, Department of Medicine, Boston, MA, USA.

Received: 23 September 2020 Accepted: 30 September 2020
Published online: 06 October 2020

References
1. Centers of Disease Control and Prevention. Alzheimer’s Disease and Healthy Aging: The Truth About Aging and Dementia. 2020. https://www.cdc.gov/aging/publications/features/dementia-not-normal-aging.html. Accessed 15 Aug 2020.
2. National Institutes on Aging. Basics of Alzheimer’s Disease and Dementia: What is Alzheimer’s Disease? 2017. https://www.nia.nih.gov/health/what-alzheimers-disease. Accessed 20 Aug 2020.
3. Mitchell SL, Mor V, Harrison J, McCarthy EP. Embedded pragmatic trials in dementia care: realising the vision of the NIA IMPACT Collaboratory. J Am Geriatr Soc. 2020;68(Suppl 2):S1–S14.
4. World Health Organization. 10 Facts on Dementia. 2019. https://www.who.int/features/factfiles/dementia/en/. Accessed 21 Aug 2020.
5. Rizzi L, Rosset I, Rortz-Cruz M. Global epidemiology of dementia: Alzheimer’s and vascular types. Biomed Res Int. 2014;2014:908915.
6. Alzheimer’s Disease International. Dementia Statistics. https://www.alz.co.uk/research/statistics. Accessed 1 Sept 2020.
7. BioMed Central Ltd. Dementia - an interdisciplinary approach. Isr J Health Policy Res. 2019; https://www.biomedcentral.com/collections/dementia. Accessed 3 Sept 2020.
8. Sternberg SA, Sabar R, Katz G, Segal R, Fux-Zach L, Grofman V, et al. Home hospice for older people with advanced dementia: a pilot project. Isr J Health Policy Res. 2019;8(1):42.
9. Cohen-Mansfield J. Who is informed and who uninformed? Addressing the legal barriers to progress in dementia research and care. Isr J Health Policy Res. 2019;8(1):17.
10. Lorey P. Fake bus stops for persons with dementia? On truth and benevolent lies in public health. Isr J Health Policy Res. 2019;8(1):28.
11. Schweda M. Medical gazes and meteorological metaphors: representations of dementia in contemporary motion pictures. Isr J Health Policy Res. 2019;8(1):18.
12. Brody AA, Barnes DE, Chodosh J, Galvin JE, Hepburn KW, Troxel AB, et al. Building a National Program for pilot studies of embedded pragmatic clinical trials in dementia care. J Am Geriatr Soc. 2020;68(Suppl 2):S14–S20.
13. Harrison J. Embedded Pragmatic Trials for Alzheimer’s Disease: Difficult to Define and Implement, but Desperately Needed: Embedded Pragmatic Trials for Alzheimer’s Disease: Difficult to Define and Implement, but Desperately Needed: AcademyHealth [Blog]. 2020. https://www.academyhealth.org/blog/2020/01/embedded-pragmatic-trials-alzheimers-disease-difficult-define-and-impliment-desperately-needed. Accessed 10 Aug 2020.
14. Golander H. Mini research projects as a mechanism to improve the quality of dementia care. Isr J Health Policy Res. 2019;8(1):16.
15. Bentur N, Sternberg SA. Dementia care in Israel: top down and bottom up processes. Isr J Health Policy Res. 2019;8(1):22.
16. Hanson LC, Bennett AV, Jonsson M, Kelley A, Ritchie C, Saliba D, et al. Selecting outcomes to ensure pragmatic trials are relevant to people living with dementia. J Am Geriatr Soc. 2020;68(Suppl 2):S55–S61.
17. Baier RR, Jutkowitz E, Mitchell SL, McCready E, Mor V. Readiness assessment for pragmatic trials (RAPT): a model to assess the readiness of an intervention for testing in a pragmatic trial. BMC Med Res Methodol. 2019;19(1):156.
18. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020 Mar 10. https://doi.org/10.1002/alz.12068. Online ahead of print.
19. Graske J, Schmidt A, Wolf-Ostermann K. More staff = better quality of life for people with dementia? Results of a secondary data analysis in German shared-housing arrangements. Isr J Health Policy Res. 2019;8(1):26.
20. Quinones AR, Mitchell SL, Jackson JD, Aranda MP, Dilworth-Anderson P, McCarthy EP, et al. Achieving health equity in embedded pragmatic trials for people living with dementia and their family caregivers. J Am Geriatr Soc. 2020;68(Suppl 2):S58–S13.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.